Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Comparison of Two Exercise Protocols on Vascular Function and Subclinical Predictors of Cardiovascular Risk in Patients With Cardiovascular Disease

NCT07929701 is registered in ClinicalTrials.gov with University of Miami as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07929701 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
A Comparison of Two Exercise Protocols on Vascular Function and Subclinical Predictors of Cardiovascular Risk in Patients With Cardiovascular Disease
Lead sponsor
University of Miami
Phase
Not applicable
Overall status
Not yet recruiting
Start date
January 31, 2027
Completion date
January 31, 2028
Enrollment
200 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cardiovascular disease (cvd)

Arms

As registered; 3 arms.

  • High-intensity Functional Training (HIFT) Group ExperimentalHigh-Intensity Functional Training (HIFT)

    Participants assigned to the HIFT group will perform supervised high-intensity functional training using scalable, multi-joint functional movements three days per week for a total of 12 weeks.

  • Moderate-Intensity Continuous Training (MICT) Group ExperimentalModerate-Intensity Continuous Training (MICT)

    Participants assigned to the MICT group will perform supervised moderate-intensity continuous aerobic exercise three days per week for a total of 12 weeks.

  • Control Group No intervention

    Participants in this group will be asked to maintain their usual diet, usual medical care, physical activity, and lifestyle behaviors.

Primary endpoints

Registered primary outcome measures; 5 primary.

  • Change in Carotid-Femoral Pulse Wave Velocity (cfPWV) Baseline and Week 12 (post-intervention)

    Carotid-Femoral Pulse Wave Velocity (cfPWV) will be measured in meters per second (m/s) as an indicator of arterial stiffness. Measurement will be obtained using the SphygmoCor XCEL device (AtCor Medical) with upper arm and thigh cuffs with carotid artery applanation tonometry to assess pulse wave transit time.

  • Change in Central Augmentation Index (cAIx) Baseline and Week 12 (post-intervention)

    Central Augmentation Index (cAIx) expressed as a percentage (%) will be assessed using the SphygmoCor XCEL device via pulse wave analysis of the central arterial waveform derived from carotid artery tonometry and peripheral blood pressure measurements.

  • Change in Mean Arterial Pressure (MAP) Baseline and Week 12 (post-intervention)

    Mean Arterial Pressure (MAP) measured in millimeters of mercury (mmHg), will be estimated using the SphygmoCor XCEL device based on an algorithm derived from peripherally measured blood pressure obtained from an automated upper arm cuff.

  • Percent Change in Flow-Mediated Dilation (FMD) Baseline and Week 12 (post-intervention)

    Flow-Mediated Dilation (FMD) will be measured using a Philips Affiniti 50 ultrasound system. FMD will be expressed as percent (%) change in brachial artery diameter from pre-occlusion baseline to peak dilation following a 5-minute forearm occlusion.

  • Change in Carotid Intima-Media Thickness (cIMT) Baseline and Week 12 (post-intervention)

    Carotid Intima-Media Thickness (cIMT), measured in millimeters (mm), will be assessed using a Philips Affiniti 50 ultrasound system. High-resolution B-mode images of the distal common carotid artery will be acquired, and mean wall thickness will be calculated from standardized image segments of the left and right carotid arteries.

Lead sponsor's other trials

University of Miami, most recent start first.

Similar trials

Same condition (Cardiovascular Diseases) and phase, most recent start first.